Life Science Investing Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel Highlighting Durable, Differentiated Profile in Sickle Cell Disease at American Society of Hematology Annual Meeting
Life Science Investing Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
Life Science Investing Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Life Science Investing Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology Annual Meeting
Life Science Investing Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
Life Science Investing Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
